Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lab-Developed Test Regs In Spotlight With Citizen Petition, Hamburg Speech

This article was originally published in The Gray Sheet

Executive Summary

The American Clinical Laboratory Association filed a citizen petition with FDA June 4 reiterating and formalizing its long-held opposition to FDA regulating laboratory-developed test services. The petition closely followed a speech from FDA Commissioner Hamburg emphasizing plans to do just that.

You may also be interested in...



FDA Chief Heads For Door; Agency's Chief Scientist Will Fill Role – For Now

FDA Commissioner Margaret Hamburg will step down at the end of March.

FDA Commish Hamburg Gets Fond Farewell

FDA Commissioner Margaret Hamburg said she will step down from the agency after six years in the post. She is being widely praised by lawmakers and industry as an effective bureaucrat who has worked to improve FDA’s regulatory processes and speed the path to market for new products.

Knowledge Is Not Enough For Enforcement In FDA’s Final Research-Use Dx Guidance

Companies are at risk of enforcement if they take direct steps to encourage use of their research-use or investigational-use only tests for clinical diagnostic indications, according to the guidance. But, in response to public comments, FDA removed references that a company knowing or having “reason to know” that a lab is inappropriately using a test is grounds for enforcement.

Related Content

Topics

UsernamePublicRestriction

Register

MT032136

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel